Discovery of novel pyrimidine-based benzothiazole derivatives as potent cyclin-dependent kinase 2 inhibitors with anticancer activity

Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma

Wei-Gang Tong, Rong Chen, William Plunkett et al. · Journal of Clinical Oncology · 2010 · 218 citations

Medicine, Oncology, Pharmacology +17

Three Mechanistically Distinct Kinase Assays Compared: Measurement of Intrinsic ATPase Activity Identified the Most Comprehensive Set of ITK Inhibitors

Mohammed A. Kashem, Richard M. Nelson, Jeffrey D. Yingling et al. · SLAS DISCOVERY · 2006 · 135 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17

Synthesis, antimicrobial and cytotoxic activities of pyrimidinyl benzoxazole, benzothiazole and benzimidazole

Dandu Seenaiah, Guda Mallikarjuna Reddy, Adivireddy Padmaja et al. · European Journal of Medicinal Chemistry · 2014 · 128 citations

Pharmacy, Medicinal Chemistry, Pharmacology +10

AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts

Kate F. Byth, Andrew P. Thomas, Gareth Hughes et al. · Molecular Cancer Therapeutics · 2009 · 122 citations

Medicine, Oncology, Pharmacology +17

Identification and Characterization of an Irreversible Inhibitor of CDK2

Elizabeth Anscombe, Elisa Meschini, Regina Mora-Vidal et al. · Chemistry & Biology · 2015 · 121 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +11